2021 Pediatric Grand Rounds | Risk Stratification and Treatment of First Relapse of B-ALL: The Children’s Oncology Group Approach

Duarte, CA US
July 22, 2021

The most recent Children's Oncology Group (COG) trial incorporates PD1 inhibition into relapsed acute lymphoblastic leukemia (ALL) therapy, which is being introduced for the first time in this context.  This trial also builds on the prior relapsed ALL trial, results of which are still being compiled.  There is a need to inform practitioners of the evidence behind the current COG trial for relapsed ALL and results from the prior trial, in order to apply the current state of the field to the management of relapsed pediatric ALL therapy. The purpose of this lecture is to update pediatric leukemia specialists on the most recent COG protocol for relapsed pediatric ALL, AALL1821.

Target Audience

City of Hope Pediatric Hematology/Oncology physicians, Advance practice practitioners, City of Hope staff and research teams.

Learning Objectives

  • Identify indications for eligibility for AALL1821, the Children's Oncology Group (COG) relapsed acute lymphoblastic leukemia (ALL) trial.
  • Examine the status of the current literature that incorporates PD1 inhibition into ALL therapy.
  • Examine current outcomes for pediatric ALL patients who received therapy as per the prior COG protocol for relapsed ALL.

Additional Information

AttachmentSize
PDF icon AB 1195 Bibliography - ALL157.63 KB
Activity summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
    City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    City of Hope designates this 2021 Pediatric Grand Rounds | Risk Stratification and Treatment of First Relapse of B-ALL: The Children’s Oncology Group Approach for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Attendance
Activity opens: 
07/22/2021
Activity expires: 
07/27/2021
Event starts: 
07/22/2021 - 12:00pm PDT
Event ends: 
07/22/2021 - 1:00pm PDT
Add to calendar: 
City of Hope
1500 E Duarte Rd
Duarte, CA 91010
United States

Virtual Meeting- Zoom

Stacy Cooper, MD   Program Director, Pediatric Hematology‐Oncology Fellowship; Assistant Professor, Oncology and Pediatrics; Johns Hopkins University School of Medicine

Dr. Cooper has indicated that she is a Consultant for Jazz Pharmaceuticals and Pfizer. 

ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: City of Hope designates this live webinar for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

The following credit type(s) are being offered for this course:

•  AMA PRA Category 1™  1.0

The following may apply AMA PRA Category 1 Credit™ for license renewal:

Registered Nurses: Nurses may report up to 1.0 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.

Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
    City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    City of Hope designates this 2021 Pediatric Grand Rounds | Risk Stratification and Treatment of First Relapse of B-ALL: The Children’s Oncology Group Approach for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Attendance
Please login or register to take this activity.